{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:01:13Z","timestamp":1785333673325,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shenzhen Science and Technology Program","award":["JCYJ20220531092214032"],"award-info":[{"award-number":["JCYJ20220531092214032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04553-6","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:39:28Z","timestamp":1756895968000},"page":"2593-2605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ND-630, an acetyl-CoA carboxylase inhibitor, prevents renal fibrosis in adenine-induced CKD mice"],"prefix":"10.1007","volume":"399","author":[{"given":"Xinhui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"issue":"2","key":"4553_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","volume":"29","author":"N Alkhouri","year":"2020","unstructured":"Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI (2020) GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 29(2):135\u2013141. https:\/\/doi.org\/10.1080\/13543784.2020.1668374","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"4553_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A et al (2022) Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol 77(3):607\u2013618. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.003","journal-title":"J Hepatol"},{"issue":"6","key":"4553_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41419-021-03850-1","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Dai Y, Song K, Huang Y, Zhang L, Zhang C et al (2021) Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism. Cell Death Dis 12(6):572. https:\/\/doi.org\/10.1038\/s41419-021-03850-1","journal-title":"Cell Death Dis"},{"issue":"40","key":"4553_CR4","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.2174\/1381612825666191119094354","volume":"25","author":"Y Dong","year":"2019","unstructured":"Dong Y, Qu X, Wu G, Luo X, Tang B, Wu F et al (2019) Advances in the detection, mechanism and therapy of chronic kidney disease. Curr Pharm des 25(40):4235\u20134250. https:\/\/doi.org\/10.2174\/1381612825666191119094354","journal-title":"Curr Pharm des"},{"key":"4553_CR5","doi-asserted-by":"publisher","unstructured":"Escasany E, Lanz\u00f3n B, Garc\u00eda-Carrasco A, Izquierdo-Lahuerta A, Torres L, Corrales P, et al (2021) Transforming growth factor \u03b23 deficiency promotes defective lipid metabolism and fibrosis in murine kidney. Dis Model Mech 14(9). https:\/\/doi.org\/10.1242\/dmm.048249","DOI":"10.1242\/dmm.048249"},{"key":"4553_CR6","doi-asserted-by":"publisher","unstructured":"Fr\u0105k W, D\u0105bek B, Balcerczyk-Lis M, Motor J, Radzioch E, M\u0142ynarska E, et al. (2024) Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease. Antioxidants (Basel) 13(6). https:\/\/doi.org\/10.3390\/antiox13060687","DOI":"10.3390\/antiox13060687"},{"key":"4553_CR7","doi-asserted-by":"publisher","first-page":"794629","DOI":"10.3389\/fphys.2021.794629","volume":"12","author":"J Geng","year":"2021","unstructured":"Geng J, Liu Y, Dai H, Wang C (2021) Fatty acid metabolism and idiopathic pulmonary fibrosis. Front Physiol 12:794629. https:\/\/doi.org\/10.3389\/fphys.2021.794629","journal-title":"Front Physiol"},{"key":"4553_CR8","doi-asserted-by":"publisher","first-page":"113377","DOI":"10.1016\/j.biopha.2022.113377","volume":"153","author":"G Harley","year":"2022","unstructured":"Harley G, Katerelos M, Gleich K, de Souza DP, Narayana VK, Kemp BE et al (2022) Blocking AMPK signalling to acetyl-CoA carboxylase increases cisplatin-induced acute kidney injury and suppresses the benefit of metformin. Biomed Pharmacother 153:113377. https:\/\/doi.org\/10.1016\/j.biopha.2022.113377","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"4553_CR9","doi-asserted-by":"publisher","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","volume":"113","author":"G Harriman","year":"2016","unstructured":"Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D et al (2016) Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci U S A 113(13):E1796-1805. https:\/\/doi.org\/10.1073\/pnas.1520686113","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"4553_CR10","doi-asserted-by":"publisher","first-page":"107772","DOI":"10.1016\/j.jbc.2024.107772","volume":"300","author":"DT Hass","year":"2024","unstructured":"Hass DT, Pandey K, Engel A, Horton N, Haydinger CD, Robbings BM et al (2024) Acetyl-CoA carboxylase inhibition increases retinal pigment epithelial cell fatty acid flux and restricts apolipoprotein efflux. J Biol Chem 300(10):107772. https:\/\/doi.org\/10.1016\/j.jbc.2024.107772","journal-title":"J Biol Chem"},{"key":"4553_CR11","doi-asserted-by":"publisher","unstructured":"Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PXK, et al. (2015) Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 7(316):316ra193. https:\/\/doi.org\/10.1126\/scitranslmed.aac7071","DOI":"10.1126\/scitranslmed.aac7071"},{"key":"4553_CR12","doi-asserted-by":"publisher","unstructured":"Kayampilly P, Roeser N, Rajendiran TM, Pennathur S, and Afshinnia F (2022) Acetyl Co-A carboxylase inhibition halts hyperglycemia induced upregulation of De Novo lipogenesis in podocytes and proximal tubular cells. Metabolites 12(10). https:\/\/doi.org\/10.3390\/metabo12100940","DOI":"10.3390\/metabo12100940"},{"issue":"1","key":"4553_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G (2020) Reprogramming of fatty acid metabolism in cancer. Br J Cancer 122(1):4\u201322. https:\/\/doi.org\/10.1038\/s41416-019-0650-z","journal-title":"Br J Cancer"},{"issue":"12","key":"4553_CR14","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","volume":"16","author":"EJ Lawitz","year":"2018","unstructured":"Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ et al (2018) Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces Hepatic De Novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 16(12):1983-1991.e1983. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.042","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"4553_CR15","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1681\/asn.2018010050","volume":"29","author":"M Lee","year":"2018","unstructured":"Lee M, Katerelos M, Gleich K, Galic S, Kemp BE, Mount PF et al (2018) Phosphorylation of Acetyl-CoA carboxylase by AMPK reduces renal fibrosis and is essential for the anti-fibrotic effect of metformin. J Am Soc Nephrol 29(9):2326\u20132336. https:\/\/doi.org\/10.1681\/asn.2018010050","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4553_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.kint.2024.02.025","volume":"106","author":"LE Lee","year":"2024","unstructured":"Lee LE, Doke T, Mukhi D, Susztak K (2024) The key role of altered tubule cell lipid metabolism in kidney disease development. Kidney Int 106(1):24\u201334. https:\/\/doi.org\/10.1016\/j.kint.2024.02.025","journal-title":"Kidney Int"},{"issue":"5","key":"4553_CR17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","volume":"155","author":"R Loomba","year":"2018","unstructured":"Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M et al (2018) GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology 155(5):1463-1473.e1466. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.027","journal-title":"Gastroenterology"},{"issue":"2","key":"4553_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G et al (2021) Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73(2):625\u2013643. https:\/\/doi.org\/10.1002\/hep.31622","journal-title":"Hepatology"},{"key":"4553_CR19","doi-asserted-by":"publisher","first-page":"e8115","DOI":"10.7717\/peerj.8115","volume":"7","author":"Y Lu","year":"2019","unstructured":"Lu Y, Su X, Zhao M, Zhang Q, Liu C, Lai Q et al (2019) Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH. PeerJ 7:e8115. https:\/\/doi.org\/10.7717\/peerj.8115","journal-title":"PeerJ"},{"key":"4553_CR20","doi-asserted-by":"publisher","unstructured":"Miguel V, Titua\u00f1a J, Herrero JI, Herrero L, Serra D, Cuevas P, et al (2021) Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis. J Clin Invest 131(5). https:\/\/doi.org\/10.1172\/jci140695","DOI":"10.1172\/jci140695"},{"issue":"7","key":"4553_CR21","doi-asserted-by":"publisher","first-page":"e4114","DOI":"10.1002\/cbf.4114","volume":"42","author":"S Mishra","year":"2024","unstructured":"Mishra S, Shelke V, Gaikwad AB (2024) Acyl-CoA synthetase long-chain isoenzymes in kidney diseases: mechanistic insights and therapeutic implications. Cell Biochem Funct 42(7):e4114. https:\/\/doi.org\/10.1002\/cbf.4114","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"4553_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12944-024-02021-3","volume":"23","author":"L Peng","year":"2024","unstructured":"Peng L, Wang C, Yu S, Li Q, Wu G, Lai W et al (2024) Dysregulated lipid metabolism is associated with kidney allograft fibrosis. Lipids Health Dis 23(1):37. https:\/\/doi.org\/10.1186\/s12944-024-02021-3","journal-title":"Lipids Health Dis"},{"issue":"11","key":"4553_CR23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig F, Schulze A (2016) The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 16(11):732\u2013749. https:\/\/doi.org\/10.1038\/nrc.2016.89","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4553_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","volume":"16","author":"M Ruiz-Ortega","year":"2020","unstructured":"Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR (2020) Targeting the progression of chronic kidney disease. Nat Rev Nephrol 16(5):269\u2013288. https:\/\/doi.org\/10.1038\/s41581-019-0248-y","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"4553_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10565-025-09991-9","volume":"41","author":"Y Sun","year":"2025","unstructured":"Sun Y, Li B, Song B, Xia Y, Ye Z, Lin F et al (2025) UHRF1 promotes calcium oxalate-induced renal fibrosis by renal lipid deposition via bridging AMPK dephosphorylation. Cell Biol Toxicol 41(1):39. https:\/\/doi.org\/10.1007\/s10565-025-09991-9","journal-title":"Cell Biol Toxicol"},{"issue":"1","key":"4553_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bbrc.2017.11.145","volume":"495","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Kume S, Maeda S, Osawa N, Takeda N, Chin-Kanasaki M et al (2018) Overexpression of acetyl CoA carboxylase \u03b2 exacerbates podocyte injury in the kidney of streptozotocin-induced diabetic mice. Biochem Biophys Res Commun 495(1):1115\u20131121. https:\/\/doi.org\/10.1016\/j.bbrc.2017.11.145","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4553_CR27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1186\/s12967-023-04760-w","volume":"21","author":"YP Wu","year":"2023","unstructured":"Wu YP, Zheng WC, Huang Q, Huang XY, Lin F, Ke ZB et al (2023) ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003. J Transl Med 21(1):877. https:\/\/doi.org\/10.1186\/s12967-023-04760-w","journal-title":"J Transl Med"},{"issue":"7","key":"4553_CR28","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/jcph.2427","volume":"64","author":"IR Younis","year":"2024","unstructured":"Younis IR, Nelson C, Weber EJ, Qin AR, Watkins TR, Othman AA (2024) Pharmacokinetics and safety of firsocostat, an acetyl-coenzyme a carboxylase inhibitor, in participants with mild, moderate, and severe hepatic impairment. J Clin Pharmacol 64(7):878\u2013886. https:\/\/doi.org\/10.1002\/jcph.2427","journal-title":"J Clin Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04553-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:53:20Z","timestamp":1770882800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04553-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4553"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04553-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental procedure received approval from the Experimental Animal Ethics Committee of Shenzhen Glorybay Biotech Co., Ltd (approved ID: RW-IACUC-24\u20130110).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}